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COMBINED LUNG AND 
LIVER TRANSPLANTATION 
IN PATIENTS WITH 
CYSTIC FIBROSIS 
A 41A-year experience 
Patients with cystic fibrosis who have end-stage respiratory failure and 
associated liver cirrhosis have been considered poor candidates for lung 
transplantation because of high morbidity and mortality resulting from 
hepatic insufficiency after the operation. Since April 1989, our policy has 
been to combine heart-lung or lung and liver transplantation i  this group 
of patients. Between June 1990 and March 1995, among 25 patients 
accepted in the program for combined transplantation, ine died awaiting 
transplantation and 10 underwent one of the following procedures: heart- 
lung-liver transplantation ( = 5), en bloc double lung-liver transplanta- 
tion (n = 1), sequential double lung-liver transplantation (n = 3), and 
bilateral obar lung transplantation from a split left lung and reduced liver 
transplantation ( = 1). There were 5 male and 5 female patients. The ages 
of the recipients ranged from 10 to 24 years. Mean forced expiratory volume 
in 1 second was 29% and mean forced vital capacity was 35% of predicted 
values. All patients were infected with resistant Pseudomonas, three with 
Pseudomonas cepaceia, and two patients had Aspergillus pecies in addition. 
All patients had severe cirrhosis with portal hypertension. Four patients 
had a history of esophageal variceal bleeding and two had had previous 
portosystemic shunts. The operation was performed as a two-stage proce- 
dure, the intrathoracic operation being completed before the abdominal 
stage was begun. Cardiopulmonary b pass was used in all patients because 
of poor clinical condition. Immunosuppression consisted of azathioprine, 
cyclosporine, and prednisone, as for isolated lung transplantation. There 
were two perioperative deaths, one caused by primary liver failure and the 
second by early lung dysfunction. For the first 3 months after transplan- 
tation pulmonary infection was the most common cause of morbidity. Other 
complications included tracheal stenosis (n = 1), bronchial stenosis (n = 
1), biliary stricture (n = 2), and severe ascites (n = 3). All were successfully 
treated. Obliterative bronchiolitis developed in three patients. This was 
stabilized with FK 506 in two patients; the other patient underwent 
retransplantation at 38 months but eventually died of bleeding. Actuarial 
survival was 70% at 1 year and remained unchanged at 3 years. Significant 
functional improvement was observed in all survivors. For patients who 
have chronic respiratory failure with advanced cirrhosis, lung transplan- 
tation combined with liver transplantation can be performed with a 
satisfactory outcome. (J THORAC CARDIOVASC SURG 1995;110:1415-23) 
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Ystic fibrosis (CF) is a multisystem genetic dis- 
ease carried by 5% of the population. It is 
characterized by widespread isturbance of electro- 
lytic transport and protein excretion in exocrine 
glands. Pulmonary disease, exocrine pancreatic in- 
sufficiency with malabsorption, and diabetes melli- 
tus are frequently present in patients with CFJ  
Despite new therapies uch as uridine triphosphate, 
deoxyribonuclease, and amiloride, life expectancy is 
approximately 50% at 30 years. 2 Once bronchopul- 
monary infection is established, most patients with 
CF will die of severe bronchiectasis caused by 
inspissated pulmonary secretions. 
Hepatic multilobar cirrhosis occurs in 5% to 15% 
of patients with CF, 3 with onset in the first decade of 
life, and progresses to portal hypertension, hyper- 
splenia, and variceal bleeding. 4 For those patients 
liver transplantation is the only effective treatment 
option to improve length of survival and quality of 
life. To date, the presence of associated significant 
lung destruction has prevented many teams from 
embarking on liver transplantation because only 
combined replacement of irreversibly damaged lung 
and liver could offer hope of prolonged survival. 
In this study we have analyzed our results with 
combined lung and liver transplantation i  patients 
who had CF combined with end-stage lung and liver 
disease. 
Patients and methods 
Between April 1989 and March 1995, 25 patients with 
CF were referred and accepted for lung and liver trans- 
plantation in Broussais Hospital. The condition of the 
patients was assessed by physicians experienced in the 
treatment of patients with CF, and a concensus was 
reached by the CF French Transplant group regarding the 
suitability and acceptance of candidates. Patients were 
selected for associated procedures (i.e., heart-lung-liver or 
double lung-liver transplantation) onthe basis of a dete- 
riorating clinical status indicating a limited life expect- 
ancy. Evidence of critically ill condition was suggested by 
(1) more frequent hospitalizations for pulmonary infec- 
tion and loss of functional lung capacity, (2) complications 
of portal hypertension such as variceal hemorrhage, (3) 
emaciation despite parenteral feeding, (4) necessity for 
nasal intermittent positive-pressure ventilation for severe 
hypoxemia nd hypercapnia used for sudden deteriora- 
tions and as a bridge to lung transplantation, 5 and (5) 
life-threatening pulmonary and liver complications such 
as pneumothorax, hemoptysis, or severe gastrointestinal 
bleeding. 
All patients accepted for the combined procedure had 
severely compromised pulmonary function. The mean 
forced vital capacity was 34% and the mean forced 
expiratory volume in 1 second was 29% of predicted 
values. All patients were hypoxic, requiring supplemental 
oxygen. All had end-stage liver disease with severe cirrho- 
sis and portal hypertension, and all had esophageal varices 
as seen with an endoscope. One patient had hepatopul- 
monary syndrome with severe hypoxemia and an intrapul- 
monary shunt of 35% despite good results of pulmonary 
function tests. The clinical status of all patients i  outlined 
in Table I. Sputum cultures before transplantation grew 
mainly Pseudomonas species (Table II). 
Prospective candidates were evaluated to identify rela- 
tive contraindications to transplantation, which included 
poor nutritional status and renal dysfunction. Controlled 
diabetes mellitus, previous thoracic surgery (lobectomy, 
pleurodesis), and colonization of sinuses or respiratory 
passages are no longer considered to be contraindications. 
Because waiting periods for transplantation can be 
protracted and the condition of the patients often de- 
teriorates during this time, all patients in this group 
participated in a preoperative program of pulmonary 
rehabilitation, with regular intensive physiotherapy. 
Noninvasive mechanical ventilation was instituted if re- 
quired in deteriorating situations of severe hypoxemia and 
hypercapnia. Patients with inadequate nutritional status 
benefited from parenteral nutrition or jejunostomy feed- 
ing. In cases of chronically infected paranasal sinuses, 
bilateral antral washouts or antrostomies were per- 
formed. 6 At the beginning of our experience when heart- 
lung transplantations were being performed, recipients 
were all evaluated and accepted for domino procedures. 
Donor organs and procurement. Donors were selected 
on the basis of standard criteria for separate heart-lung or 
lung transplantation a d liver transplantation. The follow- 
ing factors were particularly important: good pulmonary 
function as determined by an arterial oxygen tension of 
150 mm Hg or greater at an inspired oxygen concentration 
of 40%, adequate size matching, chest roentgenogram 
showing no abnormalities, viral studies negative for hu- 
man immunodeficiency virus (human T-cell lymphotropic 
virus types I and II) and hepatitis B and C, ABO 
compatibility, no history of lung disease, negative sputum 
Grain stain results, and short periods of mechanical 
ventilation. Only persons who smoked heavily were not 
accepted as donors. Unless transplantation was urgent, 
cytomegalovirus mismatching was not accepted for a 
recipient negative for cytomegalovirus. For the liver to be 
accepted, normal liver function test results were required. 
Donor operation. In each case, all organs were ob- 
tained from a single donor by means of standard harvest- 
ing techniques. Before retrieval of the heart and lungs, all 
donors were given heparin intravenously (250 U/kg) and a 
bolus of intravenous methylprednisolone (1 gin). Prosta- 
glandin E 1 (1000 /xg) was administered irectly and 
rapidly into the pulmonary artery, Cold Papworth solution 
(20 mg/kg) was then infused into the pulmonary artery 
with simultaneous infusion of crystalloid cardioplegic so- 
lution into the ascending aorta for heart and lung preser- 
vation. 7 The liver graft was cooled and preserved with 
University of Wisconsin solution as described elsewhere. 8 
Recipient operation. The combined but separate pro- 
cedures of thoracic and abdominal organ transplantation 
were performed in the same operative sitting. All opera- 
tions, including the three cases of sequential double lung 
transplantation, were performed with the use of cardio- 
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pulmonary bypass because of the critical nature of the 
recipient's condition. We proceeded with liver transplan- 
tation after completion of the lung implantation, termina- 
tion of bypass, and reversal of heparinization. The ster- 
notomy remained open as the liver transplantation was 
done to allow access for temporary portoatrial shunting. 
This was needed in two patients. The sternotomy and 
chest wound were closed before the biliary anastomosis 
was fashioned to minimize the risk of contamination. 
We performed heart-lung transplantation i the first 
five patients with a full-sized liver in four and a partial 
liver in one patient to achieve proper size matching. As 
the technique of lung transplantation evolved, we per- 
formed a bilateral en bloc technique in one patient with 
direct revascularization f bronchial arteries. 9 This proce- 
dure was complex, and the next three patients had bilat- 
eral sequential double lung implantations in combination 
with liver transplantation. Most recently, for a major size 
discrepancy between the donor and recipient, we per- 
formed a bilateral sequential lobar transplantation from a 
split left lung associated with a reduced liver lobe trans- 
plantation. From a left lung bipartition, the upper lobe 
was implanted into the right side of the thorax and the 
lower lobe into the left pleural cavity. 1° This patient 
received a partial liver (left lobe). Another patient with a 
large thorax but a small abdominal cavity underwent a
standard heart-lung procedure and received apartial iver 
(left lobe). Techniques of partial liver transplantation 
have been described elsewhere. 11
Median sternotomy was used for heart-lung and double 
lung en bloc techniques. An anterior bilateral thoracot- 
omy via the fourth or fifth intercostal space was used for 
sequential double lung transplantation. 12 During the re- 
moval of the infected lung, care was taken to minimize 
pleural contamination. The bronchus of the native lung 
was stapled distal to the line of division, and open 
proximal bronchi were suctioned with disposable devices. 
The donor bronchus was divided as close to the hilum as 
possible. 13 The pleurae were irrigated with povidone- 
iodine solution after explantation of the recipient's lung. 
A telescoping technique of anastomosis was used for the 
tracheal anastomosis. Bronchial anastomoses were per- 
formed by an end-to-end technique with a continuous 
running suture without omentopexy and without elescop- 
ing of the bronchi. 
Liver transplantation was straightforward in seven pa- 
tients. In three patients who had had previous abdominal 
operations I two portosystemic shunts and one laparotomy 
exploration for meconium ileus, the operation was tech- 
nically more difficult and intraoperative blood loss was 
increased. So that ischemic time could be minimized, 
preliminary preparation of the liver was done during 
implantation of the lungs. This was particularly useful in 
the two patients who received a reduced-size liver. Biliary 
reconstruction was by choledochocholedochostomy with a
T-tube in two patients or Roux-en-Y choledochojejunos- 
tomy in eight patients. 
Postoperative management 
[mmunosuppression. Postoperative immunosuppression 
was based on our standard triple-drug therapy for isolated 
lung transplantation--azathioprine, 2 to 3mg/kg, together 
with three doses of equine antithymocyte globulin and 
Table I. Patient clinical status 
No. of 
Status patients 
End-stage respiratory failure 
(FEV~ = 29%; FVC = 34%) 
Dependent on supplementary oxygen 10 
History of hemoptysis/pneumothorax 5 
Hepatopulmonary syndrome 1 
End-stage liver failure 
Cirrhosis and portal hypertension 10 
Hepatic failure 3 
History of variceal bleeding 6 
Previous portosystemic shunts 2 
FEV1, Forced expiratory volume in 1 second; FVC, forced vital capacity. 
Table II. Infection status before transplantation 
No. of 
Organism patients 
Pseudomonas eruginosa 9 
Pseudomonas cepacia 2 
Pseudomonas maltophilia 1 
Staphylococcus aureus 4 
Aspergillus 4 
Candida 2 
methylprednisolone (1 gm at operation and 125 mg three 
times daily for the first 24 hours). Steroids were then 
withheld for 8 days and resumed at a dosage of 1 mg/kg 
per day, tapering to 0.2 mg/kg per day by 6 months. 
Cyclosporine was given intravenously (1 to 2.5 mg/kg per 
day) for 8 days (doses being adjusted according to renal 
function and concentration of cyclosporine in the blood). 
Oral cyclosporine was then started to maintain a serum 
level of 150 to 250 mg/ml. Episodes of acute lung rejection 
were controlled with bolus intravenous doses of methyl- 
prednisolone (15 mg/kg for 3 days) for grade I or II 
rejection. 14 Antithymocyte globulin was added for persis- 
tent grade I to II rejection or for grade III rejection. 
Rejection was diagnosed on clinical grounds in the first 
postoperative week and thereafter on results of transbron- 
chial biopsy. Postoperative management i  the early phase 
was aimed toward maintenance of optimum hemodynam- 
ics with restriction of fluid intake to avoid pulmonary 
edema and to allow early extubation. Bronchoscopic 
examination, transbronchial biopsy, and bronchoalveolar 
lavage were performed routinely and when indicated on 
clinical grounds. Ultrasonography of the liver with Dopp- 
ler evaluation of the hepatic artery and portal vein were 
done daily. 
Results 
From April 1989 through March 1995, 25 patients 
with CF were accepted onto the transplant waiting 
list for combined heart-lung-liver or lung-liver trans- 
plantation. Ten patients underwent transplantation: 
heart-lung transplantation was done in five patients, 
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Table III. Demographic haracteristics of CF 
recipients 
Children Adults 
(n =4)  (n - 6) 
Age (yr) 11 (10-12)* 20.8 (17-24) 
Weight (kg) 29.5 (23-38) 47.6 (42-55) 
Height (cm) 136 (122-154) 166 (154-173) 
Gender (M/F) 2/2 3/3 
*Values in parentheses are ranges. 
Table IV. Perioperative data 
Ischemic time (min) 
Heart lung 229 _+ 7.5 
First lung 125 _+ 5.4 
Second lung 191 -+ 6.3 
Liver 620 _+ 9.2 
Duration of operation (hr) 
Mean 12 
Range 10-17 
Duration of ventilation (days) 
Mean 1 
Range 1-21 
ICU stay (days) 
Mean 17 
Range 10-60 
Hospital stay (days) 
Mean 45 
Range 10-90 
ICU, Intensive care unit. 
double lung in four (one with an en bloc technique 
and three with sequential bilateral lung transplants), 
and sequential bilateral lobar transplantation a d a 
reduced liver transplantation i  one. Demographic 
characteristics are depicted in Table III. The aver- 
age waiting time for transplantation was 9 months 
(range 2 to 30 months). Nine patients died on the 
waiting list, and six are currently awaiting a com- 
bined transplantation. Length of postoperative 
follow-up ranged from 9 months to 5 years. In our 
practice, the duration of waiting has been shorter for 
patients with CF accepted for isolated lung trans- 
plantation than for patients with CF accepted for 
combined transplantation (6vs 9 months). 
Perioperative outcome. Operative and postoper- 
ative data are presented in Table IV. Ischemic times 
are given for both lungs, the left lung being im- 
planted after the right lung. Ischemic time for the 
liver ranged from 390 to 780 minutes (mean 620 
minutes), which is acceptable for liver grafts pre- 
served with University of Wisconsin solution. Peri- 
operative mortality, as defined by death within the 
first 90 days after transplantation r before patients 
Table V. Mortality 
No. of 
patients 
Early mortality (<3 mo after transplantation) 
Liver graft failure (retransplantation) 1 
Lung graft failure (ECMO) 1 
Late mortality (>3 mo after transplantation) 
Cerebral hemorrhage 1 
Obliterative bronchiolitis (retransplantation) 1 
ECMO, ExtracorporeaI membrane oxygenation. 
have been discharged from the hospital, was 20% 
(two patients). One patient who had primary liver 
graft failure received a second donor liver on post- 
operative day 5, was reextubated, but subsequently 
died of unexplained pulmonary edema. One patient 
had acute lung graft failure and died despite insti- 
tution of extracorporeal membrane oxygenation. 
Causes of early and late deaths are summarized in 
Table V. Actuarial survival was 70% at 1 year and 
has remained unchanged at 3 years (Fig. 1). 
Postoperative complications are documented in 
Tables VI and VII. Airway complications occurred 
in two children--tracheal stenosis in one and bron- 
chial stricture on the right side in the patient with 
bilateral obar transplantation. Both were success- 
fully treated with laser or dilation therapy. Airway 
stenting was not used in any of these patients. Five 
patients had prolonged thoracic drainage for pleural 
effusion. 
Hepatic complications occurred in five patients. 
Two patients had ascites. In one the ascites was due 
to a chyloperitoneum, after laparotomy on postop- 
erative day 30 for ligation of lymphatic ducts around 
the hepatic pedicle, the patient recovered unevent- 
fully. In two other patients, both with choledocho- 
choledochostomy, a biliary stricture developed 3 
weeks and 6 months after the operation. These 
strictures were successfully managed by conversion 
to choledochojejunostomy. One patient had an ob- 
struction equivalent o meconium ileus. This was 
successfully relieved with meglumine diatrizoate 
(Gastrografin) enemas and acetylcysteine orally. 
Three patients have had grand mal seizures after 
transplantation. In two patients reversible cerebral 
abnormalities were identified on computed tomo- 
graphic scanning. One patient had a cerebral hem- 
orrhage in the sixth postoperative month as a result 
of systemic hypertension and eventually died. All 
patients who had seizures also had elevated systemic 
blood pressure. De novo insulin-dependent diabetes 
mellitus developed in four patients. 
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Table VI, Surgical complications 
No. of 
Complication patients 
Liver graft failure 1 
Required retransplantation 
Ascites (chyloperitoneum) 2 
Required laparotomy in 1 patient 
Biliary obstruction (strictures) 2 
CDC converted to CDJ 
Bowel obstruction 1 
Meconium ileus equivalent 
Lung graft failure 1 
Required ECMO 
Tracheal stenosis 1 
Laser and dilation 
Bronchial stenosis 1 
Dilation 
Prolonged thoracic drainage 5 
CDC, Choledbchocholedochostomy; CDJ, choledochojejunostomy; ECMO, 
extracorporeal membrane oxygenation. 
Table VII. Medical complications 
No. of 
patients 
Pulmonary infections 35 
Acute rejection episodes 
Lung 26 
Liver 8 
Obliterative bronchiolitis 3 
Seizures 3 
Toxic cardiomyopathy 1 
De novo diabetes mellitus 4 
Infection was a significant cause of morbidity 
despite antibiotic prophylaxis administered to all 
recipients; on the basis of the most recently available 
Gram stain, culture, and sensitivity of the recipient's 
upper respiratory tract. Antibiotic prophylaxis was 
given for 2 weeks and was stopped if no evidence of 
infection was present. The linearized infection rates 
were 2.2 episodes per 100 patient-days. There was a 
high predominance of bronchitis and pneumonia 
with Pseudomonas aeruginosa. Two patients had 
bronchial infections caused by Aspergillus fumigatus. 
One patient had meningoencephalitis as a result of 
herpesvirus infection. 
Rejection. Rejection episodes were more fre- 
quent during the first 3 postoperative months. 
Lung rejection episodes were four times more 
common than liver rejection episodes (26 epi- 
sodes vs eight episodes). Three long-term survi- 
vors had no rejection episodes. Acute episodes of 
lung and liver rejection were not associated in our 
series. Rejection episodes were not significantly 
El ~ [2 [~ 
% 6O 
Surviving 
4O 
20 
0 
1 6 12 18 24 30 36 
Time (months post-transplantation) 
Fig. 1. Actuarial survival (Kaplan-Meier) of patients with 
CF having combined lung-liver transplantation. 
more common in patients with CF and combined 
transplantation than in patients with isolated lung 
transplantation. 
Obliterative bronchiolitis. Obliterative bronchi- 
olitis diagnosed according to established criteria 
developed in three patients. ~5 Among two patients 
who had grade III obliterative bronchiolitis, one 
underwent retransplantation during the thirty- 
eighth postoperative month but subsequently died 
of bleeding; the second patient chose not to be 
listed for retransplantation and is currently in 
poor clinical condition. A third patient with grade 
I-II obliterative bronchiolitis has a normal life- 
style after having been treated with FK 506. 
Discussion 
Since the first clinical experience with heart-lung 
transplantation i  patients with CF was reported in 
1984, encouraging results in heart-lung and lung 
transplantation i such patients have been pub- 
lished.7, 16-1s The combination of hepatic cirrhosis 
and portal hypertension, which occurs in 5% to 15% 
of patients, may preclude a successful outcome of 
lung transplantation a d has generally been consid- 
ered to be an absolute contraindication. I  patients 
with CF, improved management of pulmonary prob- 
lems has increased life expectancy and allowed time 
for extrapulmonary complications to develop. 19 
Liver disease usually appears in the first decade of 
life. The early characteristic of hepatic lesions is a 
focal biliary fibrosis, which is thought to result 
primarily from the accumulation of abnormally te- 
nacious bile in intrahepatic ducts, impedes bile flow, 
and causes biliary fibrosis and consequent cirrhosis. 
This may progress to severe portal hypertension, as 
occurred in our 10 patients who had splenomegaly at 
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the time of assessment. The indications of hyper- 
splenism were reflected in white cell counts and 
platelets and large varices shown at endoscopy, a° 
Hepatocyte function as estimated by serum albu- 
min, prothrombin time, and transaminase values 
may be normal or slightly impaired despite ad- 
vanced multilobular cirrhosis, 4 and in our series only 
three patients had hepatic failure. 
The combination of end-stage lung and liver 
disease in these patients is particularly challenging 
for both surgical therapy and postoperative manage- 
ment. Questions have been raised regarding the 
suitability of such candidates for transplantation, 
particularly in the global context of organ short- 
age. 18 These patients are often in poor nutritional 
condition related to severe intestinal malabsorption 
and chronic infection with multiresistant organisms. 
Their poor clinical status is aggravated by portal 
hypertension with episodic life-threatening compli- 
cations such as gastrointestinal bleeding. Ileus may 
cause abdominal distention and diaphragmatic 
splinting. All of these problems may impair the 
results of combined transplantation. Despite these 
increased preoperative risk factors, our results with 
an actuarial survival of 70% at 3 years are similar to 
those reported for isolated lung transplantation i  
patients with CF, who have a good quality of 
life.18, 21 The genetic nature of the disease is such 
that recurrence in transplanted organs is highly 
unlikely. This has been demonstrated for lung trans- 
plantation 22 but not for liver transplantation. Nev- 
ertheless, in our first patient with a 5-year follow-up, 
repeated liver biopsies taken when indicated for 
suspected rejection episodes have not shown recur- 
rence of the disease. In this report, 50% of the 
patients accepted for combined transplantation died 
while awaiting a donor organ, essentially because of 
an unacceptably protracted waiting time (mean 9 
months). The regulations regarding sharing organs 
should be reconsidered togain a priority for patients 
who have combined end-stage lung and liver dis- 
ease. 
The important question, then, is when and which 
patient with CF and associated lung and liver dis- 
eases hould be referred and accepted for combined 
transplantation. Encouraging results have been re- 
ported for the treatment of portal hypertension with 
splenomegaly by isolated liver transplantation i
patients with CF. 23' 24 In these reports, patients had 
mild-to-moderate lung disease and, with a mean 
forced expiratory volume in 1 second of approxi- 
mately 70%, would certainly not be candidates for 
lung transplantation. Noble-Jamieson and col- 
leagues 24 reported an impressive improvement in 
subjective pulmonary symptoms in five children with 
CF after isolated liver transplantation, with greatly 
improved exercise tolerance and even decreased 
sputum production. Improvement in pulmonary 
function was also reported by Coxy but three 
patients of a total of 10 died of infective complica- 
tions, as a result of Pseudomonas in two and As- 
pergillus in one. Mieles and associates 23reported on 
four children and five adults; two died of operative 
problems, and pulmonary function remained stable 
or was improved in the seven survivors. In our series, 
one patient had mild lung disease but also had a 
hepatopulmonary s ndrome with extensive pulmo- 
nary shunting of 35% (as measured with albumin 
macroaggregates) and severe hypoxemia (oxygen 
tension of 35 mm Hg). 26 Isolated liver transplanta- 
tion in this syndrome has reversed hypoxemia c- 
cording to occasional reports, z7 but a recent report 
from our group has shown poor results with in- 
creased mortality in patients with hypoxemia (oxy- 
gen tension <60 mm Hg). as Therefore we consid- 
ered isolated liver transplantation contraindicated 
for this patient. 
Among the various surgical options available for 
combined transplantation, the two-stage procedure 
was adopted with completion of the heart-lung or 
bilateral sequential double lung transplantations 
befose the liver operation was done. This procedure 
allows time for the liver to be prepared during 
implantation of intrathoracic organs and thus mini- 
mizes hepatic ischemic time. The thorax was left 
unclosed to facilitate cannulations should there be a 
need for temporary portoatrial shunting for liver 
implantations. This was required in two patients and 
was done with a centrifugal pump without hepa- 
rinization. Thus dissection and implantation of the 
liver was performed without anticoagulation. This 
approach greatly facilitated organization and oper- 
ative conditions for both teams, which could work in 
good coordination but separately. Other possible 
strategies include that of Wallwork, Williams, and 
Calne, a9 who proposed the integrated but staged 
and sequential procedures with prebypass dissection 
of the heart and lung and the liver and implanta- 
tion of the liver with the aid of bypass. As the 
technique of lung transplantation has evolved, 12 the 
introduction of the anterior bithoracosternotomy 
approach for sequential bilateral ung transplanta- 
tion has meant that the separate implantation of 
lungs and liver is the only surgical option possible. 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 110, Number 5 
Couetil et al. 14 21 
Although biliary reconstruction, once considered 
the Achilles heel of liver transplantation, 3° has 
become standardized, biliary strictures remain a 
significant source of complications in our patients 
with CF, Biliary strictures developed in the only 
two patients who had biliary reconstruction by 
choledochocholedochostomy; this complication was 
managed by conversion to a Roux-en-Y chole- 
dochojejunostomy. We believe that choledochocho- 
ledochostomy should be avoided in patients with CF 
because the diseased recipient bile duct may play a 
major role in causing stricture. 
Scarcity of suitable donor organs, even more 
critical in the pediatric population, has prompted 
surgeons to develop techniques of liver ~ and pul- 
monary reductions. We ~° recently developed a tech- 
nique of split lung with the use of bilateral obar 
transplants from a donor left lung. The technique of 
combined reduced-liver and bilateral lobar lung 
transplantation was successfully performed in one 
child. Lobar transplantation from living related do- 
nors has been proposed for isolated lung 31 or liver 
transplantation i  children. 32 Discharged patients 
had dramatic improvement in pulmonary function 
as reflected by forced expiratory volume in 1 second 
and forced vital capacity, with satisfactory blood 
gases on exertion and improved quality of life 
despite the morbidity caused by complications. In- 
cidence of lung or liver rejection episodes was 
comparable with that of isolated repeated organ 
transplants, and there was no demonstrable immu- 
nosuppressive effect of an additional liver allograft 
from the same donor, as has been reported in 
clinical33 and experimental settings. 34'35 The inci- 
dence of obliterative bronchiolitis was disappoint- 
ingly high (40%). Response to augmented mainte- 
nance immunosuppression was inconsistent, but the 
condition of two patients was stabilized by con- 
verting cyclosporine therapy to FK 506. Retrans- 
plantation was performed in an additional patient. 
Retransp!antation remains controversial for obliter- 
ative bronchiolitis because of poor reported results 
and scarcity of donor organs. 36 
This report shows encouraging results for com- 
bined lung and liver transplantation with a morbid- 
ity and mortality equaling that of separate replace- 
ments. It demonstrates the feasibility and potential 
of the combined procedure in carefully selected 
patients With CF who have chronic respiratory fail- 
ure with advanced cirrhosis and thus minimal life 
expectancy. Close cooperation of clinicians with 
complementary specialist interests is of utmost im- 
portance. 
We acknowledge the nurses and medical staffs of 
Broussais and Cochin Hospitals. 
REFERENCES 
1. Penketh ARL, Wise A, Mearns MB, Hodson ME, 
Batten JC. Cystic fibrosis in adolescents and adults. 
Thorax 1987;42:526-32. 
2. Geddes DM. Cystic fibrosis: future trends in care. 
Thorax 1988;43:115-30. 
3. Scott-Jupp R, Lama M, Tanner MS. Prevalence of 
liver disease in cystic fibrosis. Arch Dis Child 1991;66: 
698-701. 
4. Feigelson J, Anagnostopoulos C, Poquet M, Pecau Y, 
Munck A, Navarro J. Liver cirrhosis in cystic fibro- 
sis-therapeutic implications and long term follow up. 
Arch Dis Child 1993;68:653-7. 
5. Hodson ME, Madden BP, Steven MH, Tsang VT, 
Yacoub MH. Non-invasive mechanical ventilation for 
cystic fibrosis patients--a potential bridge to trans- 
plantation. Eur Respir J 1991;4:524-7. 
6. Starnes VA, Lewiston N, Theodore J, et al. Cystic 
fibrosis: target population for lung transplantation in 
North America in the 1990s. J THORAC CARDIOVASC 
SURe 1992;103:1008-14. 
7. de Leval MR, Smyth R, Whitehead B, et al. Heart and 
lung transplantation for terminal cystic fibrosis: a 
41/2-year experience. J TnONAC CARDIOVASC SURG 
1991;101:633-42. 
8. Kalayoglu M, Sollinger HW, Stratta R J, et al. Ex- 
tended preservation fthe liver for clinical transplan- 
tation. Lancet 1988;1:617-9. 
9. Daly RC, Tadjkarim IS, Khaghani A, Banner NR, 
Yacoub MH. Successful double-lung transplantation 
with direct bronchial artery revascularization. Ann 
Thorac Surg 1993;56:885-92. 
10. Couetil JP, Grousset A, Benaim D, et al. Mise au 
point experimentale d  la bipartition pulmonaire avec 
transplantation lobaire bilaterale chez le chien et 
application en clinique humaine. Chirurgie 1994-95; 
120:512-7. 
11. Bismuth H, Houssin D. Reduced-sized orthotopic 
liver graft in hepatic transplantation in children. Sur- 
gery 1984;95,3:367-70. 
12. Pasque MK, Cooper JD, Kaiser LR, Haydock DA, 
Triantafillou A, Trulock EP. Improved technique for 
bilateral lung transplantation: rationale and initial 
clinical experience. Ann Thorac Surg 1990;49:785-91. 
13. Pinsker KL, Koerner SK, Kamholz SL, Hagstrom 
JWC, Veith FJ. Effect of donor bronchial length on 
healing: a canine model to evaluate bronchial anasto- 
motic problems in lung transplantation. J THORAC 
CANDIOVASC SUNG 1979;77:669-73. 
14. Yousem SA, Berry GJ, Brunt EM, et al. A working 
1 4 2 2 Couetil et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
• November 1995 
formulation for the standardization f nomenclature 
in the diagnosis of heart and lung rejection: lung 
rejection study group. J Heart Transplant 1990;9:593- 
601. 
15. Cooper JD, Bilingham M, Egan T, et al. A working 
formulation for the standardization f nomenclature 
and for clinical staging of chronic dysfunction i  lung 
allografts. J Heart Lung Transplant 1993;12:713-6. 
16. Madden BP, Hodson ME, Tsang V, Radley-Smith R, 
Khaghani A, Yacoub MH. Intermediate-term results 
of heart-lung transplantation for cystic fibrosis. Lan- 
cet 1992;June 27;339:1583-7. 
17. Ramirez JC, Patterson GA, Winton TL, de Hoyos 
AL, Miller JD, Maurer JR. Bilateral ung transplan- 
tation for cystic fibrosis. J T~OP, AC CARDIOVASC SUaG 
1992;103:287-94. 
18. Egan TM, Detterbeck FC, Mill RM, et al. Improved 
results of lung transplantation for patients with cystic 
fibrosis. J THOP, AC CARDIOVASC SURG 1995;109:224- 
35. 
19. Park RM, Grand RJ. Gastrointestinal manifestations 
of cystic fibrosis: a review. Gastroenterology 1981;81: 
1143-61. 
20. Stern RC, Stevens DP, Boat TF, Doershuk CF, Izant 
RJ Jr, Matthews LW. Symptomatic hepatic disease in 
cystic fibrosis: incidence, course, and outcome of 
portal systemic shunting. Gastroenterology 1976;70:5: 
645-9. 
21. Dennis C, Caine N, Sharples L, et al. Heart lung 
transplantation for end stage respiratory disease in 
cystic fibrosis patient at Papworth Hospital. J Heart 
Lung Transplant 1993;12:893-902. 
22. Wood A, Higgenbottam T, Jackson M, Scott J, Stew- 
art S, Wallwork J. Airway mucosal bielectric potential 
difference in cystic fibrosis after lung transplantation. 
Am Rev Respir Dis 1989;i40:1645-9. 
23. Mieles LA, Orenstein D, Teperman L, Podesta L, 
Koneru B, Starzl TE. Liver transplantation in cystic 
fibrosis. Lancet 1989;May 13:1073. 
24. Noble-Jamieson G, Valente J, Barnes ND, et al. Liver 
transplantation for hepatic irrhosis in cystic fibrOsis. 
Arch Dis Child 1994;71:349-52. 
25. Cox KL. The role of liver transplantation i  cystic 
fibrosis patients. Cystic Fibrosis Conference 1990; 
S1.4:78-9. 
26. Lange PA, Stoller JK. The hepatopulmonary s n- 
drome. Ann Intern Med 1995;122:521-9. 
27. Van Obbergh L, Carlier M, de Clety SE, et al. Liver 
transplantation a d pulmonary gas exchanges in hy- 
poxemic hildren. Am Rev Respir Dis 1993; 148:1408- 
10. 
28. Hobeika J, Houssin D, Bernard O, Devictor D, Gri- 
mon G, Chapuis Y. Orthotopic liver transplantation 
in children with chronic liver disease and severe 
hypoxemia. Transplantation 1994;57,2:224-8. 
29. Wallwork J, Williams R, Calne RY. Transplantation 
of liver~ heart, and lungs for primary biliary cirrhosis 
and primary pulmonary hypertension. Lancet 1987; 
July 25:182-5. 
30. Colonna JO II, Shaked A, Gomes AS, et al. Biliary 
strictures complicating liver transplantation. Ann 
Surg 1992;216,3:344-52. 
31. Starnes VA, Barr ML, Cohen RG. Lobar transplan- 
tation: Indications, techniques, and outcome. J THO- 
RAC CARDIOVASC SuRG 1994;108:403-11. 
32. Broelsch CE, Emond JC, Whitington PF, Thistle- 
thwaite JR, Baker AL, Lichtor JL. Application of 
reduced-size liver transplants as split grafts, auxiliary 
orthotopic grafts, and living related segmental trans- 
plants. Ann Surg 1990;212,3:368777. 
33. Gonwa TA, Nery JR, Husberg BO, Klintmalm GB. 
Simultaneous liver and renal transplantation in man. 
Transplantation 1988;46:690-3. 
34. Calne RY, Sells RA, Pena JR, et al. Induction of 
immunological tolerance by porcine liver allografts. 
Nature 1969;223:472-6. 
35. Kamada N, Davies B, Roser HS. Reversal of trans- 
plantation immunity by 1/ver grafting. Nature 1981; 
292:840-2. 
36. Smith J, Wallwork J. Retransplantation in heart-lung 
recipient with obliterative bronchiolitis [Letter]. J 
THORAC CARDIOVASC SURG 1995;109:818. 
Discussion 
Dr. Magdi Yacoub (London, England). Dr. Couetil, 
your paper aises many issues. I would like to limit myself 
to three. 
The first relates to the therapeutic potential of com- 
bined organ transplantation. Previously there was anec- 
dotal evidence from our group and others that combined 
heart, lung, and liver transplantation r heart and liver 
transplantation is worthwhile. Your report, however, show 
fairly definitively that this is a viable approach by provid- 
ing a detailed analysis of a relatively large number of 
patients. 
The second issue relates to the potential of multiorgan 
transplantation for inducing specific immune tolerance. 
We know clinically that transplantation f the lungs with 
the heart does impart specific immune tolerance to the 
heart in that acute rejection is rare. Furthermore, our 
group and others have good evidence that the incidence of 
accelerated coronary sclerosis in heart-lung transplanta- 
tion is extremely ow, again suggesting a degree of specific 
immune tolerance induced by the transplanted lung. 
Interestingly, the liver has been thought o have almost 
magical properties in inducing specific immune tolerance, 
particularly in experimental models. A variety of mecha- 
nisms have been thought to be responsible, including 
transplantation f the hepatocytes themselves ordendritic 
cells and reticuloendothelial cells or, last, through the 
secretion of soluble class I major histocompatibility com- 
plex antigens. This observation has been validated repeat- 
edly in experimental models, particularly by Sir Roy 
Calne's group. In the human being, however, this infor- 
mation again remained anecdotal. We thought we had 
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some evidence that transplantation f the liver, either with 
the heart or with the heart and lung, does have an effect in 
imparting specific immune tolerance. Our first patient 
who had heart, lung, and liver transplantation for CF is 
alive and well 9 years later with no evidence of either 
coronary sclerosis or, more important, obliterative bron- 
chiolitis, i would like you to comment on this in view of 
your statements about the incidence of acute and chronic 
rejection in these patients. 
My final point, a relatively trivial one, concerns tech- 
nique. We have found that simultaneous heart, lung, and 
liver transpiantation has advantages. While the thoracic 
surgeon is implanting the heart and lung block, another 
surgeon can easily be performing liver transplantation. 
That shortens the operating time. This approach usually is 
combined with cannulation of the femoral vein, and that 
can facilitate the anastomosis of the inferior vena cava, 
either above or below the diaphragm. After discontinuing 
bypass the inferior vena cava cannula can be left to act as 
a shunt into the right atrium through the superior vena 
cava cannula. 
Dr. Couetil. Your first question concerned the potential 
of the donor liver inducing tolerance. We were very 
disappointed in this respect, because most of our patients 
had many rejection episodes, particularly in the lungs. 
Three patients had no rejection episodes of the liver or 
lungs, but the seven other patients had many rejection 
episodes. We are aware that in clinical studies combined 
transplantation f the kidney and liver offers better esults 
regarding the number and the grade of the rejection 
episodes. We are also aware that experimental results 
have shown that when the liver is transplanted with other 
organs from the same donor, the rate of rejection episodes 
is lower. But I think that in those series the liver has 
always been transplanted before the other organs (i.e., the 
kidney in clinical studies or before the heart in experimen- 
tal studies. In our series the liver was transplanted after 
the lungs, and that may be part of the explanation for the 
lesser organ tolerance. Experimentally, it has been shown 
that if the liver is transplanted just after the other organs, 
there is no induction of tolerance. 
Your second question concerned the advantage of 
simultaneous lung and liver transplantation. Perhaps si- 
multaneous transplantation explains why you had fewer 
rejection episodes in your series than we had with sequen- 
tial implantation, the lungs first and the liver second. 
However, in defense of our technique, we implant the 
lung or the heart and lungs first and we completely 
discontinue cardiopulmonary b pass. We control hemo- 
stasis, and we start the liver transplantation as a separate 
operation. Cannulafion for an eventual portosystemic 
shunt for the liver transplantation was required in only 
two patients in our series. In eight patients it was not 
necessary. 
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